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Magnesium ferrite nanoparticles, with diameters around 25 nm, were synthesized by coprecipitation method. The 
magnetic properties indicate a superparamagnetic behavior, with a maximum magnetization of 16.2 emu/g, a coercive 
field of 22.1 Oe and a blocking temperature of 183.2 K. These MgFe2O4 nanoparticles were used to produce aqueous and 
solid magnetoliposomes, with sizes below 130 nm. The potential drug curcumin was successfully incorporated in these 
nanosystems, with high encapsulation efficiencies (above 89%). Interaction by fusion between both types of drug-loaded 
magnetoliposomes (with or without PEGylation) and models of biological membranes was demonstrated, using FRET or 
fluorescence quenching assays. These results point to future applications of magnetoliposomes containing MgFe2O4 
nanoparticles in cancer therapy, allowing combined magnetic hyperthermia and chemotherapy. 
 
 
Introduction  
Magnetic nanoparticles with superparamagnetic properties have 
attracted increased attention for applications in biomedicine, as 
they exhibit a strong magnetization only when an external magnetic 
field is applied.
1-3 
Magnetoliposomes (liposomes entrapping 
magnetic nanoparticles) are promising therapeutic systems which 
can be guided and localized to specific sites by external magnetic 
field gradients
3-5 
and used as an alternative to conventional 
chemotherapy through magnetically-controlled drug delivery and 
hyperthermia.
6-9
 
In the past few years, rising attention has been given to the 
synthesis of ferrite nanoparticles without transition metals. Calcium 
and magnesium have been proposed to substitute transition metals 
in the crystalline structure of ferrite nanoparticles, as their ions are 
safely metabolized by the human body and may promote a higher 
biocompatibility.
9,10
 In fact, in vitro cytotoxicity tests on T-cell lines 
showed that calcium ferrite nanoparticles are biocompatible at 
concentrations below 250 mg/mL, exhibiting an enhanced cell 
viability when compared to other ferrites.
11
  
Magnesium ferrite nanoparticles are less sensitive to oxidation than 
magnetite and can be used as hyperthermia agents, as they display 
a large heating capacity which generates appropriate temperatures 
for hyperthermia.
12,13
 Among all the techniques available for the 
synthesis of magnesium ferrite nanoparticles, the most used are sol 
gel, combustion and coprecipitation methods.
14-17
 In order to obtain 
smaller particles, reverse coprecipitation and reverse micelle 
methods have been proposed,
14,18-19 
 to achieve nanoparticles with 
crystallite diameters around 20 nm.
14,18
 
Curcumin is a natural polyphenolic compound with 
anti-inflammatory, antioxidant, antimicrobial and anticancer 
properties.
20
 It was demonstrated that this compound has been 
involved in the mechanisms of regulation of target molecules, 
including transcription factors, growth factors, cytokines, enzymes 
and several genes that regulate cell proliferation and apoptosis.
21
 
Considering these properties and the lack of toxicity at high doses, 
curcumin has gained increased attention as a potential therapeutic 
agent for cancer, diabetes, allergies, neurodegenerative disorders, 
arthritis and other inflammatory diseases.
22-24
 However, the 
therapeutic use of curcumin has been limited due to its 
hydrophobic character, implying low solubility and stability in 
aqueous media, and poor bioavailability (reduced absorption, rapid 
metabolism and systemic elimination). These obstacles have 
hampered the verification of the therapeutic efficacy of curcumin in 
clinical trials.
25
 In order to overcome these limitations, the use of 
drug delivery systems, such as polymeric nanoparticles, micelles, 
liposomes and hydrogels, has been increased, to improve the 
bioavailability of the compound.
24-30
  
In this work, noveI magnetoliposomes containing biocompatible 
magnesium ferrite nanoparticles were tested as nanocarriers for 
curcumin as a model drug. These studies have demonstrated 
promising results for the use of these magnetoliposomes as drug 
nanocarrier systems, with potential applications in cancer therapy.
 
Experimental 
All the solutions were prepared using spectroscopic grade solvents 
and ultrapure water (Milli-Q grade).  
Preparation of magnesium ferrite nanoparticles 
Magnesium ferrite nanoparticles were prepared by coprecipitation 
method. First, 10 mL of an aqueous solution containing 1.08 g of 
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magnesium sulfate, 1.39 g of iron(II) sulfate heptahydrate and 
200 L of a 10% sulfuric acid solution were heated at 75 ᵒC, under 
magnetic stirring, until a clear solution was obtained. Then, 1.02 g 
of potassium oxalate monohydrate were dissolved in 15 mL of 
warm deionized water. The two solutions were then mixed, under 
vigorous stirring, at 90 ᵒC. After 15 minutes, the solution was cooled 
to room temperature. The precipitated nanoparticles were washed 
by several cycles of centrifugation and redispersion in water. 
Finally, the nanoparticles were calcined at 600 ᵒC for 3 hours. 
Preparation of magnetoliposomes 
For magnetoliposomes preparation, the lipids egg yolk 
phosphatidylcholine (Egg-PC), dipalmitoyl phosphatidylcholine 
(DPPC) (from Sigma-Aldrich), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG2000, from Avanti Polar Lipids) were 
used. For aqueous magnetoliposomes preparation, a 10 mM lipid 
solution in ethanol was injected, under vigorous vortexing, to a 
dispersion of magnetic nanoparticles in ultrapure water (pH=7), 
above the melting transition temperature of the lipids, 41 C for 
DPPC and -18 C for Egg-PC (ethanolic injection method).
31
 At this 
pH, the nanoparticles are below their point of zero charge (a PZC 
value of 8.4 was reported for similar MgFe2O4 nanoparticles also 
calcined at 600 ᵒC)
32
 and thus are expected to be well dispersed at 
the time of injection. After encapsulation, an ultracentrifugation 
was performed to remove all the non-encapsulated nanoparticles. 
Solid magnetoliposomes (SMLs) were prepared by a method 
previously developed.
33,34
 First, 10 μL of the synthesized MgFe2O4 
NPs were dispersed in 3 mL of water and centrifuged. Then, the 
deposited particles were dispersed in 10 μL water in an 
ultrasonicator, for one minute at 189 W, and 3 mL of chloroform 
were added to the aqueous dispersion of NPs. After vigorous 
agitation, 165 μL of a 20 mM solution of 
dipalmitoylphosphatidylcholine (DPPC) were added under 
vortexing, to form the first lipid layer of the SMLs. The particles 
were washed twice by magnetic decantation with pure water, in 
order to remove the lipid that was not attached to the NPs. The 
second lipid layer was then formed by the injection of 165 μL of a 
lipid solution (20 mM), under vortexing, in a 3 mL aqueous 
dispersion of the particles with the first layer. The resulting SMLs 
were then washed and purified with ultrapure water by 
centrifugation. The formation of a lipid bilayer around the prepared 
magnesium ferrite nanoparticles was confirmed by Förster 
Resonance Energy Transfer (FRET) measurements, using the labeled 
lipids NBD-C12-HPC (1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-
4-yl)amino]hexanoyl}-sn-glycero-3-phosphocholine) and Rhodamine 
B-DOPE (N-(lissamine Rhodamine B sulfonyl)-1,2-dioleoyl-sn-3-
phosphatidylethanolamine (ammonium salt)), both from Avanti 
Polar Lipids (structures in Figure S1 of Supplementary Information), 
as previously described.
33,34 
Curcumin was entrapped in aqueous magnetoliposomes by the 
co-injection method, while in solid magnetoliposomes the drug was 
incorporated by injection of an ethanolic solution together with the 
formation of the second lipid layer, as already reported for the 
incorporation in magnetoliposomes of several new antitumor 
compounds.
34-36
  
Preparation of Giant Unilamellar Vesicles (GUVs) 
Soybean lecithin (L-α-Phosphatidylcholine), from Sigma-Aldrich, was 
used for GUVs preparation, using a procedure described by Tamba 
et al.
37,38 
100 μL of soybean lecithin solution (1 mM) were dried 
under an argon stream to produce a thin and homogeneous lipid 
film. 40 μL of water were added to the film and it was incubated at 
45 °C for 30 minutes. Then, 3 mL of 0.1 M glucose aqueous solution 
were added and the resulting mixture was again incubated at 37 °C 
for 2 hours. Finally, after incubation, the GUVs suspension was 
centrifuged at 14000 g for 30 minutes at 20 ᵒC, to remove 
multilamellar vesicles and lipid aggregates. 
Spectroscopic measurements  
General methods. Absorption spectra were recorded in a Shimadzu 
UV-3101PC UV-Vis-NIR spectrophotometer. Fluorescence 
measurements were performed using a Fluorolog 3 
spectrofluorimeter, equipped with double monochromators in both 
excitation and emission, Glan-Thompson polarizers and a 
temperature controlled cuvette holder. Fluorescence spectra were 
corrected for the instrumental response of the system.  
The steady-state fluorescence anisotropy, r, taken as the average 
value in an appropriate spectral range, is calculated by 
  𝑟 =
𝐼VV−𝐺𝐼VH
𝐼VV+2𝐺𝐼VH
            (1) 
where IVV and IVH are the intensities of the emission spectra 
obtained with vertical and horizontal polarization, respectively (for 
vertically polarized excitation light), and 𝐺 = 𝐼HV/𝐼HH is the 
instrument correction factor, where IHV and IHH are the emission 
intensities obtained with vertical and horizontal polarization (for 
horizontally polarized excitation light). 
FRET measurements. FRET efficiency, RET, defined as the 
proportion of donor molecules that have transferred their excess 
energy to acceptor molecules, can be obtained by taking the ratio 
of the donor integrated fluorescence intensities in the presence of 
acceptor (FDA) and in the absence of acceptor (FD) (eqn. 2),
39
 
  ΦRET  =  1 −
FDA
FD
            (2) 
The distance between donor and acceptor molecules can be 
determined through the FRET efficiency (eqn. 2),  
𝑟AD =  𝑅0. [
1−ΦRET
ΦRET
]
1
6⁄
              (3) 
where R0 is the Förster radius (critical distance), that can be 
obtained by the spectral overlap, J(λ), between the donor emission 
and the acceptor absorption, according to equations (4) and (5) 
(with R0 in Å,  in nm, A() in M
-1
 cm
-1
),
39 
𝑅0 = 0.2108[𝑘
2D
0 𝑛−4𝐽(𝜆)]
1
6⁄             (4) 
𝐽(𝜆) =  ∫ 𝐼𝐷(𝜆
∞
0
)𝜀𝐴(𝜆)𝜆
4𝑑𝜆           (5) 
where 𝑘2 = 2 3⁄
 
is the orientational factor assuming random 
orientation of the dyes, Φ𝐷
0  is the fluorescence quantum yield of 
the donor in the absence of energy transfer, n is the refraction 
index of the medium, ID(λ) is the fluorescence spectrum of the 
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donor normalized so that ∫ 𝐼𝐷
∞
0
(𝜆)𝑑𝜆 = 1, and A(λ) is the molar 
absorption coefficient of the acceptor. 
For determination of fluorescence quantum yield of NBD-C12-HPC 
(energy donor) in magnetoliposomes containing mangnesium 
ferrite nanoparticles, this fluorescent labeled lipid incorporated in 
lipid membranes was used as reference, r=0.32 at 25 ᵒC, as 
reported by Invitrogen.
40 
Structural characterization 
Scanning Electron Microscopy (SEM). SEM images of magnesium 
ferrite nanoparticles and solid magnetoliposomes were recorded 
using a Scanning Electron Microscope FEI - Nova 200 NanoSEM, 
operating in transmission mode (STEM). In the case of SMLs, a 
negative staining was employed. For that, a 2% aqueous solution of 
ammonium molybdate tetrahydrate was prepared. Then, 20 μL of 
sample and 20 μL of staining solution were mixed and a drop of this 
mixture was placed onto a Formvar grid, held by tweezers. After 20 
seconds, almost all the solution was removed with filter paper and 
left dry. The processing of STEM images was performed using 
ImageJ software. It consisted in enhancing local contrast followed 
by automatic local thresholding and particle analysis. The area of 
each particle allowed an estimation of the particle diameter. The 
resulting histograms were fitted to Gaussian distributions. 
X-Ray Diffraction (XRD) and DLS measurements. X-Ray 
Diffraction (XRD) analyses were performed using a 
conventional Philips PW 1710 diffractometer, operating with 
CuKα radiation, in a Bragg-Brentano configuration.  
Liposomes mean diameter and size distribution (polydispersity 
index) were measured using a Dynamic Light Scattering (DLS) 
equipment (NANO ZS Malvern Zetasizer) at 25 ᵒC, using a 
He-Ne laser of =632.8 nm and a detector angle of 173ᵒ. Five 
independent measurements were performed for each sample. 
 
Magnetic measurements 
General methods. Magnetic measurements were performed at 
room temperature in a Superconducting Quantum Interference 
Device (SQUID) magnetometer (Quantum Design MPMS5XL), using 
applied magnetic fields up to 5.5 T. 
Temperature dependence of the magnetization and magnetic 
hysteresis cycles. The temperature dependence of the 
magnetization was measured in the temperature range from 5 K to 
380 K. The curves were obtained by initially cooling the sample 
under an applied magnetic field of H = 100 Oe (field cooled, FC) and 
then measuring its magnetization with increasing temperature 
(applied field of H = 50 Oe). Subsequently, after reaching 350 K, the 
sample was recooled, this time with no applied magnetic field 
(zero-field-cooled, ZFC) and the magnetization measurements were 
again performed with increasing temperature, under the same 
magnetic field of H = 50 Oe. From the behavior of the FC and ZFC 
curves, the blocking temperature (TB) of the superparamagnetic 
nanoparticles can be obtained.
41
 The magnetization hysteresis loop 
measurements were made by fixing the temperature and 
measuring the magnetization at a series of different applied 
magnetic fields. This type of study gives information about the 
maximum magnetization and the degree at which the sample 
remains magnetized when the applied field is removed, and how 
easily the sample magnetization can be reversed, the so-called 
coercive field. 
Curcumin Encapsulation Efficiency 
The encapsulation efficiency, EE(%), of curcumin in 
magnetoliposomes was determined through fluorescence emission 
measurements. After preparation, drug-loaded magnetoliposomes 
(MLs) were subjected to centrifugation at 10000 rpm for 60 
minutes. The supernatant was pipetted out and its fluorescence 
was measured, allowing to determine the drug concentration using 
a calibration curve previously obtained. Three independent 
measurements were performed for each system and standard 
deviations (SD) were calculated. The encapsulation efficiency was 
determined using the following equation: 
𝐸𝐸(%) =
(𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 − 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑛𝑜𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑟𝑢𝑔)
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡
× 100         
(6) 
Results and discussion 
Nanoparticles characterization 
XRD analysis. XRD measurements allowed confirming the synthesis 
of the magnesium ferrite nanoparticles. A calcination process at 
600 ᵒC was needed to obtain a crystalline phase. All the 
characteristic peaks for a pure crystalline phase of magnesium 
ferrite spinel,
19,42
 marked by their indices (MgFe2O4, space group 
F d -3 m:1, CIF 1011245, are shown in Figure 1. For Rietveld analysis 
using FullProf software,
43
 the background was defined by a linear 
interpolation between a set of points at fixed scattering angles, but 
with fitted intensities. It was impossible to obtain good fits when 
considering a direct spinel structure of type Mg
Td
Fe2
Oh
O4 as 
indicated in CIF 1011245. As the peaks (2 2 0) and (4 4 0) have 
increased intensities when compared to that of the main peak, 
(3 1 1), inclusion of preferential orientation correction at (1 1 0) 
plane
36
 resulted in a small but insufficient improvement (Table S1 in 
Supplementary Information). Considering that the spinel structure 
has a cation ordering according to Mg
Td
(1-i)Fe
Td
iMg
Oh
iFe
Oh
(2-i)O4, the 
Rietveld optimization resulted in a reasonable fit for a degree of 
inversion, i, of 0.897, with χ
2 
= 2.92 and a RF factor of 6.8. The use of 
preferential orientation correction improved the fitting quality 
parameters to χ
2 
= 2.35 and RF = 5.03, with i = 0.825. The 
corresponding average size is 33 nm. 
The obtained values for the degree of inversion are within the 
reported values of 0.56 
44
 and 0.9,
45
 and depend on the preparation 
method and crystallite size, as it was demonstrated for the case of 
ZnFe2O4.
46
  
Scanning Electron Microscopy. STEM images of the 
nanoparticles prepared by the procedure here described 
revealed generally spherical nanoparticles uniform in size, with 
a size distribution of 24.5 ± 8.7 nm (Fig. 2). This size compares 
well with the ones reported by Chandradass et al.,
14
 who 
prepared nanopowders with 19.6 ±
 
2 nm diameter (although 
by a different method, the reverse microemulsion), and also by 
Kanagesan et al.,
15 
who obtained nanoparticles with diameters 
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around 20 nm. Maensiri and coworkers
42
 also prepared 
MgFe2O4 nanoparticles (incorporated in electrospun 
polyvinylpyrrolidone (PVP) nanofibers) with sizes increasing 
from 15 ± 4 nm to 24 ± 3 nm, when the calcination 
temperature was raised from 500 to 800 °C. Here, the size 
distribution obtained by STEM is roughly in accordance with 
the one estimated by XRD. 
UV-Visible absorption spectra. The UV-Visible absorption (or 
transmission) spectrum of the synthesized magnesium ferrite 
nanoparticles allows obtaining the optical band gap using a Tauc 
plot,
47
 which corresponds to equation (7): 
 
   gEhναhν n                                           (7) 
where α is the absorption coefficient that is proportional to 
the absorbance, n is an exponent that depends on the nature 
of the transition (being n=2 for a direct semiconductor and 
n=1/2 for an indirect one), and Eg is the optical band gap. 
A linear relation was only obtained for n=2 (Fig. 3) indicating that 
MgFe2O4 behaves as a direct semiconductor. 
 
 
Fig. 1 XRD pattern of the MgFe2O4 nanoparticles calcined at 600 °C and Rietveld analysis using preferential orientation correction at the 
(1 1 0) plane, a fitted background represented by a dashed line and considering either direct (A) or 82.5% inverted (B) spinel structure.  
 
 
 
Fig. 2 A. STEM image of MgFe2O4 nanoparticles. B. Particles size 
histogram of image A and fitting to a Gaussian distribution. 
 
 
Fig. 3 Tauc plot for magnesium ferrite nanoparticles. Inset: 
UV-Visible transmission spectra of NPs dispersed in water.  
 
A band gap of 1.41 eV was estimated from the intercept of 
Tauc plot (Fig. 3), in good agreement with the results of 
Manikandan et al.,
48
 but somewhat lower than the value of 2.0 
eV reported by Kim and coworkers.
49 
 
A 
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Magnetic properties. Figure 4 displays the temperature 
dependence of the magnetization measured with zero field cooled 
(ZFC) and field cooled (FC) curves in the temperature range from 5 K 
to 350 K. The blocking temperature (TB) distributions of MgFe2O4 
nanoparticles were determined by the temperature derivative of 
the difference between the ZFC and FC magnetization curves (inset 
of Fig. 4). Here, the maximum (Tmax = 183.23 K), corresponds to the 
blocking temperature of the main size distribution.
50
 This method 
has shown to be more accurate than the one that considers TB as 
the maximum of the ZFC curve,
51
 as the dipolar interactions result 
in a shift of the ZFC maximum to higher temperatures.  
Figure 5 shows the magnetization hysteresis cycle of magnesium 
ferrite nanoparticles. The maximum magnetization value at 50 kOe, 
16.2 emu/g, is slightly smaller than the one obtained by Maensiri et 
al.
42
 for MgFe2O4 nanoparticles incorporated in electrospun PVP 
nanofibers also calcined at 600 ᵒC, but higher than those reported 
by Kaur et al.
16
 for NPs prepared by different chemical methods 
(including coprecipitation). As previously observed by Chandradass 
et al.
14
 and Maensiri et al.,
42
 a saturation was not attained in the 
magnetization hysteresis loop, maybe due to the presence of 
surface defects. Chandradass and coworkers
14 
prepared magnesium 
ferrite NPs with a maximum magnetization of Ms=12.9 emu/g also 
by coprecipitation. Maensiri and coworkers
42
 reported that 
calcination at higher temperatures (700 – 800 ᵒC) of MgFe2O4/PVP 
nanocomposites causes an increase in the maximum magnetization, 
but also in both Hc and Mr, with the loss of superparamagnetism of 
the NPs (for superparamagnetic nanoparticles, Mr/Ms < 0.1). 
 
 
Fig. 4 Temperature dependence of the magnetization (ZFC and 
FC) of MgFe2O4 nanoparticles over the temperature range 
5 ‒ 350 K, with H=50 Oe. Inset: Temperature derivative of the 
difference between ZFC and FC magnetization curves. 
 
A decrease of the magnetization of oxide nanoparticles can be 
caused by surface effects, like a surface disordered or a 
magnetically dead surface layer.
52
 Moreover, the relative amount of 
Fe
3+
 ions at A (Td) and B (Oh) positions in the nanocrystal may 
strongly decrease the maximum magnetization, since the spins of 
ions in A and B sites magnetize oppositely the corresponding 
sublattices in the incomplete inverse spinel structure.
53  
Nevertheless, the nanoparticles here obtained stand out 
considering the low coercive field (Hc) and residual magnetization 
(Mr), indicating that most of the nanoparticles shows a 
superparamagnetic behavior (Mr/Ms =0.02, Table 1). 
 
 
Fig. 5 Magnetization hysteresis loop of MgFe2O4 NPs measured at 
room temperature. Inset: Enlargement of the loop, in the low field 
region. 
 
Table 1. Coercive field (HC), maximum magnetization (Ms), remnant 
magnetization (Mr) and ratio Mr/MS for magnesium ferrite NPs. 
SQUID data available at https://doi.org/10.5061/dryad.482q2rh 
HC (Oe) MS (emu/g) Mr (emu/g) Mr/MS 
22.1 16.16 0.26 0.02 
 
The critical size (in zero or a small field), D, for superparamagnetic 
behaviour can be obtained by
54 
𝐷 =  √
6𝑘B𝑇 ln(𝑡m𝑓0)
𝜋𝐾
3
                               (9) 
where K is the anisotropy constant, f0 is the frequency constant 
(10
9
 Hz), kB is the Boltzmann’s constant, T the absolute 
temperature and tm is the time of measurement. An anisotropy 
constant of 0.61×10
5
 erg cm
-3
 is reported for MgFe2O4,
55
 leading to 
a critical size for superparamagnetic behaviour of about 33 nm, at 
room temperature. Thus, the size of MgFe2O4 nanoparticles here 
obtained (both by XRD and SEM) is in accordance with the 
superparamagnetic behavior predicted by SQUID measurements. 
The inductive heating capability of magnetic nanoparticles, under 
an alternating current magnetic field, is directly proportional to the 
area of the hysteresis cycle and thus rises as the coercive field is 
increased, decreasing with the diminution of the maximum 
magnetization.
56
 Here, the significant coercive field (22.1 Oe, Table 
1) compensates the lower maximum magnetization of MgFe2O4 
nanoparticles when compared to that of other ferrites (nickel, 
manganese, iron or cobalt),
33,34,50
 and points to a possible 
application of these nanoparticles in magnetic hyperthermia 
therapies. The negative effect of the lower Ms value of MgFe2O4 on 
the inductive heating capability can also be compensated by the 
occurrence of small clusters of magnetic nanoparticles, that 
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originate an additional and significant heating capacity, enough to 
reach therapeutic temperatures, as already reported.
57
 
Comparing with transition metal ferrite nanoparticles previously 
incorporated in solid and aqueous magnetoliposomes (namely, 
nickel ferrite and manganese ferrite),
33-35
 magnesium ferrite 
nanoparticles have the advantage of guaranteed 
biocompatibility,
9,10
 not compromising the superparamagnetic 
behaviour. Considering magnetite, despite the reported 
biocompatibility, it has been shown that these nanoparticles are 
sensitive to oxidation, being transformed into maghemite in the 
presence of oxygen.
58
 Moreover, it has been described that iron 
oxide nanoparticles induce the production of reactive oxygen 
species (ROS) in mammalian cells,
59 
causing severe DNA and protein 
damage and inflammatory responses.
60,61
 Therefore, magnesium 
ferrite nanoparticles can be advantageous, avoiding these 
undesirable effects. 
 
Characterization of magnetoliposomes 
DLS and SEM measurements. Two types of magnetoliposomes 
were obtained, solid magnetoliposomes (SMLs) and aqueous 
magnetoliposomes (AMLs). The biocompatibility of magneto-
liposomes (containing MnFe2O4 nanoparticles) of the same lipids 
and prepared by the same techniques was previously reported.
35
 
Aqueous magnetoliposomes were prepared by ethanolic injection 
of the lipids
31
 in the aqueous ferrofluid. This methodology was 
chosen because it is very advantageous for hydrophobic drugs
62
 (as 
is the case of curcumin, exhibiting a very limited solubility in 
aqueous media), which can be loaded into magnetoliposomes by 
coinjection. Dynamic Light Scattering (DLS) measurements were 
used to characterize aqueous magnetoliposomes containing 
MgFe2O4 nanoparticles. These systems exhibit diameters of 122 ± 
19 nm (size distribution in Fig. S2 of Supplementary Information), 
with a low polydispersity (below 0.2). This result is similar to the 
one reported recently for AMLs of the same lipid containing iron 
oxide nanoparticles,
36
 however being somewhat higher than those 
of AMLs containing transition metal ferrites.
33,34
 For enhanced 
permeability and retention (EPR) effect of loaded drugs, the size of 
magnetoliposomes must be small, and a successful extravasation 
into tumors has been shown to occur for nanocarriers with sizes 
below 200 nm.
63
 
Solid magnetoliposomes (SMLs) were obtained by coverage of a 
cluster of magnesium ferrite NPs by the phospholipid DPPC, using 
the method previously developed for Ni ferrite and Mn ferrite 
nanoparticles.
33,34
 Following the same procedure, the formation of 
the lipid double layer was proven by FRET, Rhodamine B-DOPE 
labeling the first lipid layer of magnetoliposomes and the second 
lipid layer containing NBD-C12-HPC. Upon double layer formation, a 
strong energy transfer is observed from NBD (donor) to Rhodamine 
B (acceptor), with a FRET efficiency of 73% (Fig. S3 in 
Supplementary Information). Using eqns. (3) to (5), a 
donor-acceptor distance of 3.8 nm proves the formation of the lipid 
bilayer around the nanoparticles cluster, which has a typical 
thickness between 7 and 9 nm.
64 
SEM images of SMLs (obtained 
with a negative staining) revealed that the synthesized solid 
magnetoliposomes present diameters slightly above 100 nm (Fig. 
6). Fig. 6A exhibits several magnetoliposomes containing 
nanoparticles clusters (with one smaller cluster in the middle). A 
single magnetoliposome is observed in Fig. 6B. The size obtained is 
slightly smaller than those of SMLs of DPPC containing MnFe2O4 and 
Fe3O4 nanoparticles.
35,36 
As reported previously,
35
 the interest in 
using a DPPC bilayer in SMLs is the melting transition temperature 
of this phospholipid (Tm =
 
41 ᵒC),
65
 approaching the temperatures 
used in mild hyperthermia therapy. An additional increase in 
membrane fluidity is expected upon lipid phase transition (from the 
gel to the liquid crystalline phase), with a potential enhancement in 
drug release capability of the solid magnetoliposomes. 
 
 
Fig. 6 SEM images of solid magnetoliposomes (SMLs) containing 
magnesium ferrite nanoparticles (obtained with a negative 
staining). 
 
Incorporation of curcumin in AMLs and SMLs. The potential drug 
curcumin is fluorescent in several polar and non-polar solvents (Fig. 
S4 in Supplementary Information). The absorption and emission 
bands of curcumin can be attributed to the enol-keto tautomer,
66
 
while in water/ethanol and water/acetonitrile mixtures the 
existence of the diketo tautomer was reported.
67,68
 Large spectral 
red shifts, band enlargement and loss of vibrational structure are 
observed for the emission in polar media (Fig. S4), this behavior 
being attributed to a strong intramolecular charge transfer 
mechanism in the excited state, as well as to hydrogen bonding in 
protic solvents.
68
 
Curcumin was loaded into both AMLs and SMLs containing MgFe2O4 
NPs. Figure 7 shows the emission spectra of this dye in AMLs, SMLs 
and liposomes without magnetic nanoparticles (but with the same 
concentration of compound), which allow concluding that curcumin 
is fully incorporated in these nanosystems, as it is non-emissive in 
aqueous media. It is also possible to observe a quenching effect of 
the fluorophore emission by the magnetic nanoparticles, much 
more pronounced in SMLs, similarly to what was reported for other 
potential drugs and different magnetic nanoparticles.
34-36
 Also, a 
small red shift in emission is detected in liposomes and AMLs, when 
compared to SMLs, indicating a more hydrated environment for 
curcumin in the latter nanosystems, which was expected 
considering that SMLs do not contain an interior aqueous volume. 
Fluorescence anisotropy measurements (Table 2) were performed 
to confirm that curcumin is fully incorporated in both types of 
A B 
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magnetoliposomes, located mainly in the lipid bilayer. First, the 
anisotropy values are generally high at room temperature, but 
smaller (as expected) the one measured in the highly viscous 
solvent glycerol (viscosity around 1000 cP), which is much more 
viscous than lipid membranes, the latter possessing viscosities of 
100-200 cP.
69,70
 Also, the transition from the gel phase (at 25 ᵒC) to 
the liquid crystalline phase (at 55 ᵒC) of DPPC is detected by 
curcumin through a decrease in its fluorescence anisotropy; finally, 
anisotropy values are roughly similar in magnetoliposomes and neat 
liposomes. However, the anisotropy in SMLs at room temperature 
is smaller than the one in AMLs or liposomes. Although possible 
differences in the fluorophore excited-state lifetime can occur, it is 
known that lipid membrane viscosity decreases from the surface to 
the interior.
71,72
 This can justify the lower r value in SMLs, indicating 
that curcumin is located deeply in SMLs membranes. 
 
 
Fig. 7 Fluorescence spectra (exc=420 nm) of curcumin (3×10
-6
 M) in 
liposomes (without magnetic NPs), aqueous magnetoliposomes 
(AMLs) and solid magnetoliposomes (SMLs) containing magnesium 
ferrite nanoparticles. 
 
Table 2. Steady-state fluorescence anisotropy (r) values for 
curcumin in liposomes (for comparison), aqueous 
magnetoliposomes (AMLs) and solid magnetoliposomes (SMLs). 
Spectral data available at https://doi.org/10.5061/dryad.482q2rh  
 Lipid formulation Temperature r  
a 
Liposomes
 
Egg-PC 25 °C 0.331
 
DPPC  
25 °C 0.287 
55 °C 0.119 
AMLs 
Egg-PC 25 °C 0.328 
DPPC 
25 °C 0.291 
55 °C 0.147 
SMLs DPPC 
25 °C 0.141 
55 °C 0.113 
a
 Anisotropy of curcumin in glycerol is 0.365 at 25 ᵒC.
73
 
 
The curcumin encapsulation efficiencies in both AMLs and SMLs are 
presented in Table 3. Values of encapsulation efficiencies are larger 
than 89%, the lowest EE% being observed in solid 
magnetoliposomes. These high encapsulation efficiencies point to a 
promising use of these nanocarriers for hydrophobic drugs and as 
agents for simultaneous chemotherapy and magnetic 
hyperthermia.  
 
Table 3. Encapsulation efficiencies (EE%) and standard deviations 
(SD) of curcumin in aqueous and solid magnetoliposomes. Original 
data available at https://doi.org/10.5061/dryad.482q2rh 
System EE% ± SD 
AMLs (Egg-PC) 98.4 ± 1.4 
SMLs (DPPC) 89.5 ± 8.0 
 
These results also show the suitability of the ethanolic injection 
method for the preparation of curcumin-loaded magnetoliposomes.  
Using the same methodology, Jaafar-Maalej et al.
62
 reported 
encapsulation efficiencies in liposomes above 87% for another 
hydrophobic drug (beclomethasone dipropionate, BDP), attaining 
100% in some cases. The EE% values in Table 3 are also similar to 
the ones previously reported for magnetoliposomes containing new 
antitumor thienopyridine derivatives.
35 
Taking advantage of curcumin fluorescence, the non-specific 
interaction of both types of drug-loaded magnetoliposomes with 
giant unilamellar vesicles (GUVs) was monitored, using GUVs as 
models of cell membranes,
37,38
 allowing to investigate the 
possibility of drug release by fusion. For that purpose, Förster 
Resonance Energy Transfer (FRET) was employed, using curcumin as 
the energy donor and the hydrophobic dye Nile Red (widely used as 
lipid probe)
74-77
 as the energy acceptor. This is a very favorable 
donor-acceptor pair, as evaluated by the spectral overlap between 
curcumin emission and Nile Red absorption (Fig. S5 in 
Supplementary Information). Therefore, a high FRET efficiency is 
expected if the donor-acceptor distance is below 100 Å, this 
efficiency strongly decreasing with the increase in the 
donor-acceptor distance.
39
 
If magnetoliposomes interact with model membranes (GUVs) and 
fusion between them occurs, a larger membrane will be created 
and an increase in the donor-acceptor distance will be verified, with 
a corresponding decrease in the energy transfer efficiency. This was 
verified for aqueous magnetoliposomes, when these nanosystems 
were loaded with both curcumin and Nile Red (Fig. 8). Two emission 
bands, the first due to curcumin fluorescence (max=510 nm) and 
the second due to Nile Red emission (max=630 nm) are detected, if 
only curcumin is excited (Fig. 8A). After interaction with GUVs, an 
increase in the curcumin (donor) fluorescence band and a decrease 
of the Nile Red (acceptor) emission band is observed, proving the 
diminution of FRET efficiency, as a result of membrane fusion. 
In order to prevent the adsorption of plasma proteins 
(opsonization) and promote the shielding from proteolytic enzymes, 
increasing the retention time in the circulation system,
78,79
 
PEGylation of Egg-PC aqueous magnetoliposomes was carried out, 
aiming at obtaining longer-circulating nanosystems in the blood 
flow. This was achieved by using 5% of DSPE-PEG-2000 in the lipid 
composition. It has been reported that the coating with PEG is 
effective in increasing the circulation time of magnetite 
nanoparticles covered with oleic acid
79
 and of magnetoliposomes.
6
 
However, recently it was also shown that PEGylation can reduce the 
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interaction of magnetoliposomes with cells, with a corresponding 
decrease in the degree of internalization.
80 
Fluorescence anisotropy of curcumin in PEGylated Egg-PC AMLs 
(r=0.341) is very similar to the one in non-PEGylated 
magnetoliposomes of the same lipid (Table 2). The interaction with 
GUVs was equally investigated (Fig. 8B). It was observed a 
diminution of FRET efficiency, indicating fusion with GUVs, however 
in a lower extent than for non-PEGylated systems. These results 
point to a higher resistance of PEGylated AMLs to interaction with 
GUVs, but still maintaining some fusogenic capability. 
In the case of solid magnetoliposomes, the emission of curcumin in 
SMLs incorporating also Nile Red is completely suppressed, as it 
suffers fluorescence quenching from the nanoparticles and also by 
energy transfer to the acceptor Nile Red. Therefore, an assay was 
made with SMLs containing only curcumin. Upon interaction with 
GUVs, an unquenching effect of the drug fluorescence is detected, 
proving membrane fusion (Fig. 9A). A similar effect upon interaction 
with model membranes was detected previously for SMLs 
containing manganese ferrite nanoparticles
34
 and magnetite 
nanoparticles
36
 loaded with other antitumor drugs. A small red shift 
of curcumin fluorescence after interaction with GUVs may indicate, 
as previously referred, a slightly more hydrated environment felt by 
the drug after membrane fusion. 
 
Fig. 8 Fluorescence spectra (exc=420 nm) of aqueous magnetoliposomes (AMLs) based on MgFe2O4 NPs and containing both curcumin and 
Nile Red, before and after interaction with GUVs. A. AMLs of egg phosphatidylcholine. B. PEGylated AMLs. Inset: Schematic representation 
of membrane fusion between AMLs and GUVs. 
 
  
Fig. 9 Fluorescence spectra (exc=420 nm) of curcumin in SMLs containing MgFe2O4 nanoparticles, before and after interaction with GUVs. 
A. SMLs of DPPC. B. PEGylated SMLs. Inset: Schematic representation of membrane fusion between SMLs (loaded with curcumin) and 
GUVs. 
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Concerning PEGylated SMLs, containing 95% DPPC and 5% 
DSPE-PEG-2000, the fluorescence anisotropy of curcumin loaded in 
these systems was determined as r=0.153 at 25ᵒ C and r=0.109 at 
55ᵒ C. Again, the r values are similar to the ones measured in SMLs 
without PEG (Table 2). Upon interaction with GUVs, the 
unquenching effect of curcumin fluorescence is also detected in 
PEGylated SMLs (Fig. 9B) and even in a higher degree, which can 
indicate that the presence of PEG may facilitate the fusion of SMLs 
with membranes.  
Overall, these results show that the aqueous and solid drug-loaded 
magnetoliposomes, containing superparamagnetic magnesium 
ferrite nanoparticles, are promising as therapeutic agents, 
presenting the capability of being guided with a magnetic field to 
the therapeutic site and release the loaded drug by fusion with the 
cell membrane, while allowing the simultaneous application of 
magnetic hyperthermia therapy. Moreover, the application of an 
alternating magnetic field (AMF), causing a local temperature 
increase by the magnetic nanoparticles, will also promote an 
increase in fluidity of the lipid membrane of magnetoliposomes, 
enhancing drug release.   
 
Conclusions 
In this work, magnesium ferrite nanoparticles with sizes 
around 25 nm and a superparamagnetic behaviour were 
synthesized. These nanoparticles were used for the 
preparation of magnetoliposomes, both aqueous (liposomes 
entrapping magnetic nanoparticles, AMLs) and solid (magnetic 
nanoparticles covered by a lipid bilayer, SMLs), with sizes 
below 130 nm. 
The model drug curcumin was successfully incorporated in 
both AMLs and SMLs, with high encapsulation efficiencies. 
Fluorescence emission measurements (FRET or fluorescence 
quenching) indicate that curcumin-loaded AMLs and SMLs 
interact with models of cell membranes (GUVs) by fusion, even 
when PEGylation is used. 
To our knowledge, it is the first time that solid and aqueous 
magnetoliposomes containing superparamagnetic magnesium 
ferrite nanoparticles were prepared and their potentialities as 
drug nanocarriers evaluated. These results point to future 
applications of magnetoliposomes containing MgFe2O4 
nanoparticles in dual cancer therapy (combining magnetic 
hyperthermia and chemotherapy). 
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